China · Delayed Price · Currency is CNY BeBetter Med Company Description
BeBetter Med Inc., a biopharmaceutical company, engages in the research and development, and sale of drugs for oncology, metabolic diseases and central nervous system degenerative diseases.
It offers BEBT-908, a PI3K/HDAC dual-target small molecule inhibitor for antitumor; developing BEBT-209, a CDK4/6 selective inhibitor for metastatic triple-negative breast cancer; and BEBT-109, a selective EGFR inhibitor designed for NSCLC.
The company also develops BEBT-503, an oral, well-balanced pan-PPAR for metabolic diseases including diabetes and mash; BEBT-507, a GalNAc-siRNA drug for Polycythemia Vera (PV); and BEBT-701, a GalNAc-siRNA therapeutic for treatment of hypertension with co-existing hyperlipidemia.
In addition, it provides BEBT-809, a small molecule inhibitor for obesity; BEBT-706, for ASCVD risk reduction; BEBT-720, for mash; BEBT-758, for the treatment of Parkinson's disease; BEBT-756, for Alzheimer's disease; BEBT-730, for hyperuricemia and gout; BEBT-733, for renal anemia/CKD; and BEBT-738, for diabetes.
The company was founded in 2012 and is based in Guangzhou, China.
| Country | China |
| Founded | 2012 |
| Industry | Pharmaceutical Preparations |
| Employees | 160 |
| CEO | Changgeng Qian |
Contact Details
Address: Building A-3, No. 25 Yayingshi Road Guangzhou, 510663 China | |
| Phone | 86 20 3203 8087 |
| Website | bebettermed.cn |
Stock Details
| Ticker Symbol | 688759 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Changgeng Qian | Chief Executive Officer |
| Tianyi Zhang | Chief Financial Officer |